Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988448 | 0.90 | MEN1 (0.45) | KMT2AAKR1C3AKR1C1PKM | |
| SCHEMBL4988327 | 0.89 | GBA1 (0.48) | KMT2ALMNAPKM | |
| SCHEMBL4983020 | 0.89 | MEN1 (0.47) | KMT2AAKR1C3POLBL3MBTL1PKM | |
| SCHEMBL4986140 | 0.89 | CNR1 (0.38) | MAPTAKR1C3AKR1C1CNR1TP53 | |
| SCHEMBL4992564 | 0.88 | MEN1 (0.47) | KMT2AMAPTAKR1C3AKR1C1LMNA | |
| SCHEMBL4988779 | 0.87 | TDP1 (0.45) | KMT2AMAPTAKR1C3AKR1C1L3MBTL1 | |
| SCHEMBL4988642 | 0.87 | MAPT (0.43) | KMT2AMAPTAKR1C3AKR1C1LMNA | |
| SCHEMBL4987925 | 0.86 | HDAC6 (0.44) | KMT2AAKR1C3L3MBTL1ATM | |
| SCHEMBL4987011 | 0.86 | PKM (0.46) | KMT2AMAPTLMNAL3MBTL1PKM | |
| SCHEMBL4980960 | 0.85 | SMN1; SMN2 (0.46) | KMT2AMAPTAKR1C3LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885MAPT 4477/4885AKR1C3 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.